Regeneron Pharmaceuticals (REGN) free cash flow

Free cash flow · fiscal 2025
$3.77B

Regeneron Pharmaceuticals (REGN) generated free cash flow of $3.77B in fiscal 2025 (the year ended December 31, 2025). That is 6.4% higher than the $3.54B of fiscal 2024. Figures as of 18 Nov 2026, 12:41 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$3.77B
Change on fiscal 2024
+6.4%
Growth, 5 years
+13.4% a year
Growth, 10 years
+19.2% a year
Highest on record
$6.53Bfiscal 2021
Lowest on record
-$198.90Mfiscal 2011
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Regeneron Pharmaceuticals free cash flow, in more detail

Over the five fiscal years to 2025 free cash flow grew at a compound 13.4% a year; over ten years the rate was 19.2% a year. Across the 18 fiscal years on record (2008–2025), the highest was $6.53B in fiscal 2021 and the lowest -$198.90M in fiscal 2011.

History · 18 fiscal years

Free cash flow by fiscal year

Regeneron Pharmaceuticals free cash flow, year by year

Regeneron Pharmaceuticals (REGN) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$3.77B 6.4% up
2024$3.54B 3.5% down
2023$3.67B 7.9% up
2022$3.40B 48.0% down
2021$6.53B 225.9% up
2020$2.00B 0.2% up
2019$2.00B 10.4% up
2018$1.81B 75.2% up
2017$1.03B 6.2% up
2016$974.00M 49.2% up
2015$652.85M 55.7% up
2014$419.43M 3.0% down
2013$432.27M—
2012-$123.95M—
2011-$198.90M—
2010-$467.00K—
2009-$167.25M—
2008-$123.94M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Regeneron Pharmaceuticals and comparable companies
CompanyFree cash flowFiscal year
Moderna MRNA-$2.08B2025
CVS Health CVS$7.81B2025
HCA Healthcare HCA$7.69B2025
GSK GSK£4.76B2025
Regeneron Pharmaceuticals REGN$3.77B2025
Elevance Health ELV$3.17B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on REGN

Regeneron Pharmaceuticals, figure by figure

Regeneron Pharmaceuticals (REGN) overview: price, valuation and scorecardAll health care companies by market value

Regeneron Pharmaceuticals free cash flow: questions and answers

What is Regeneron Pharmaceuticals's free cash flow?

Regeneron Pharmaceuticals (REGN) generated free cash flow of $3.77B in fiscal 2025 (the year ended December 31, 2025). That is 6.4% higher than the $3.54B of fiscal 2024.

What is the growth rate of Regeneron Pharmaceuticals's free cash flow?

Over the five fiscal years to 2025 free cash flow grew at a compound 13.4% a year; over ten years the rate was 19.2% a year.

What are the highest and lowest free cash flow figures on record for Regeneron Pharmaceuticals?

Across the 18 fiscal years on record (2008–2025), the highest was $6.53B in fiscal 2021 and the lowest -$198.90M in fiscal 2011.

How is Regeneron Pharmaceuticals's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Regeneron Pharmaceuticals it is on record here for 18 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Regeneron Pharmaceuticals (REGN) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/REGN/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.